These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 3785144

  • 41. Competition between deferiprone, desferrioxamine and other chelators for iron and the effect of other metals.
    Sheppard LN, Kontoghiorghes GJ.
    Arzneimittelforschung; 1993 Jun; 43(6):659-63. PubMed ID: 8352819
    [Abstract] [Full Text] [Related]

  • 42. PCTH: a novel orally active chelator for the treatment of iron overload disease.
    Lovejoy DB, Kalinowski D, Bernhardt PV, Richardson DR.
    Hemoglobin; 2006 Jun; 30(1):93-104. PubMed ID: 16540421
    [Abstract] [Full Text] [Related]

  • 43. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
    Link G, Pinson A, Hershko C.
    Blood; 1994 May 01; 83(9):2692-7. PubMed ID: 8167347
    [Abstract] [Full Text] [Related]

  • 44. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
    Florence A, Ward RJ, Peters TJ, Crichton RR.
    Biochem Pharmacol; 1992 Sep 25; 44(6):1023-7. PubMed ID: 1417929
    [Abstract] [Full Text] [Related]

  • 45. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG, Gupta G, Estes WE, Rosenkrantz H, Metterville JJ, Crumbliss AL, Palmer RA, Nordquest KW, Hardy KA, Whitcomb DR, Byers BR, Arceneaux JE, Gaines CG, Sciortino CV.
    J Pharmacol Exp Ther; 1979 Jan 25; 208(1):12-8. PubMed ID: 759605
    [Abstract] [Full Text] [Related]

  • 46. Mobilization of iron by chiral and achiral anionic 3-hydroxypyrid-4-ones.
    Molenda JJ, Jones MM, Johnston DS, Walker EM, Cannon DJ.
    J Med Chem; 1994 Dec 09; 37(25):4363-70. PubMed ID: 7996548
    [Abstract] [Full Text] [Related]

  • 47. Development of an HPLC method for measuring orally administered 1-substituted 2-alkyl-3-hydroxypyrid-4-one iron chelators in biological fluids.
    Goddard JG, Kontoghiorghes GJ.
    Clin Chem; 1990 Jan 09; 36(1):5-8. PubMed ID: 2297936
    [Abstract] [Full Text] [Related]

  • 48. Iron removal from milk and other nutrient media with a chelating resin.
    Feng M, van der Does L, Bantjes A, de Groote JM.
    J Dairy Sci; 1995 Jan 09; 78(1):55-61. PubMed ID: 7738259
    [Abstract] [Full Text] [Related]

  • 49. Biliary excretion of plasma non-transferrin-bound iron in rats: pathogenetic importance in iron-overload disorders.
    Brissot P, Zanninelli G, Guyader D, Zeind J, Gollan J.
    Am J Physiol; 1994 Jul 09; 267(1 Pt 1):G135-42. PubMed ID: 8048526
    [Abstract] [Full Text] [Related]

  • 50. Novel orally active iron chelators (3-hydroxypyridin-4-ones) enhance the biliary excretion of plasma non-transferrin-bound iron in rats.
    Zanninelli G, Choudury R, Loréal O, Guyader D, Lescoat G, Arnaud J, Verna R, Cosson B, Singh S, Hider RC, Brissot P.
    J Hepatol; 1997 Jul 09; 27(1):176-84. PubMed ID: 9252093
    [Abstract] [Full Text] [Related]

  • 51. Design, synthesis, and biological evaluation of aromatic ester prodrugs of 1-(3'-hydroxypropyl)-2-methyl-3-hydroxypyridin-4-one (CP41) as orally active iron chelators.
    Liu ZD, Liu DY, Lu SL, Hider RC.
    Arzneimittelforschung; 2000 May 09; 50(5):461-70. PubMed ID: 10858874
    [Abstract] [Full Text] [Related]

  • 52. Design, synthesis and evaluation of N-basic substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotrophic potential.
    Liu ZD, Khodr HH, Lu SL, Hider RC.
    J Pharm Pharmacol; 2000 Mar 09; 52(3):263-72. PubMed ID: 10757413
    [Abstract] [Full Text] [Related]

  • 53. Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values.
    Liu ZD, Piyamongkol S, Liu DY, Khodr HH, Lu SL, Hider RC.
    Bioorg Med Chem; 2001 Mar 09; 9(3):563-73. PubMed ID: 11310590
    [Abstract] [Full Text] [Related]

  • 54. New orally active iron chelators.
    Kontoghiorghes GJ.
    Lancet; 1985 Apr 06; 1(8432):817. PubMed ID: 2858689
    [No Abstract] [Full Text] [Related]

  • 55. Iron chelators induce apoptosis in proliferating cells.
    Hileti D, Panayiotidis P, Hoffbrand AV.
    Br J Haematol; 1995 Jan 06; 89(1):181-7. PubMed ID: 7833261
    [Abstract] [Full Text] [Related]

  • 56. Free radical and cytotoxic effects of chelators and their iron complexes in the hepatocyte.
    Mostert LJ, Van Dorst JA, Koster JF, Van Eijk HG, Kontoghiorghes GJ.
    Free Radic Res Commun; 1987 Jan 06; 3(6):379-88. PubMed ID: 3508452
    [Abstract] [Full Text] [Related]

  • 57. 2-Hydroxypyridine-N-oxides: effective new chelators in iron mobilisation.
    Kontoghiorghes GJ.
    Biochim Biophys Acta; 1987 Apr 16; 924(1):13-8. PubMed ID: 3828392
    [Abstract] [Full Text] [Related]

  • 58. Influence of iron chelators, 1,2-dialkyl-3-hydroxypyridin-4-ones, on the lipid peroxidation and glutathione level in the liver of mice.
    Eybl V, Caisová D, Koutenský J, Kontoghiorghes GJ.
    Arch Toxicol Suppl; 1991 Apr 16; 14():185-7. PubMed ID: 1805729
    [No Abstract] [Full Text] [Related]

  • 59. Rhodamine labeling of 3-hydroxy-4-pyridinone iron chelators is an important contribution to target Mycobacterium avium infection.
    Moniz T, Nunes A, Silva AM, Queirós C, Ivanova G, Gomes MS, Rangel M.
    J Inorg Biochem; 2013 Apr 16; 121():156-66. PubMed ID: 23384853
    [Abstract] [Full Text] [Related]

  • 60. The development of new iron-chelating drugs.
    Grady RW, Graziano JH, Akers HA, Cerami A.
    J Pharmacol Exp Ther; 1976 Feb 16; 196(2):478-85. PubMed ID: 1255491
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.